VOLITIONRX LTD

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

VNRX$0.18-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(Expressed in United States Dollars, except share numbers)

	For the Years Ended
	December 31, 2024	December 31, 2023
	$	$
Revenues
Royalty	-	1,369
Service	228,138	175,476
Product	1,005,373	598,457
Total Revenues	1,233,511	775,302
Operating Expenses
Research and development	14,406,486	19,551,523
General and administrative	8,487,562	10,368,314
Sales and marketing	5,364,433	6,843,160
Total Operating Expenses	28,258,481	36,762,997
Operating Loss	(27,024,970)	(35,987,695)
Other Income (Expenses)
Grant income	103,368	214,451
Loss on disposal of fixed assets	(34,731)	(15,843)
Interest income	9,947	93,324
Interest expense	(340,362)	(221,622)
Gain on change in fair value of warrant liability	28,763	240,311
Total Other Income (Expenses)	(233,015)	310,621
Net Loss	(27,257,985)	(35,677,074)
Net Loss attributable to Non-Controlling Interest	290,149	357,996
Net Loss attributable to VolitionRx Limited Stockholders	(26,967,836)	(35,319,078)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	141,691	16,843
Net Comprehensive Loss	(27,116,294)	(35,660,231)
Loss Per Common Share Attributable to Common Stockholders - Basic and Diluted	(0.31)	(0.50)
Weighted Average Shares Outstanding – Basic and Diluted	86,531,172	71,234,565
(The accompanying notes are an integral part of these consolidated financial statements)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.